

Table 2. Benefits in survival times and survival rates judged sufficient to make worthwhile 1 year of sorafenib versus no adjuvant therapy according to randomly allocated treatment group and time of assessment.

		Time of assessment of patients' preferences											
		Baseline		3 months			15 months			42 months			Overall post-baseline
Treatment group		Sorafenib	Placebo	Sorafenib	Placebo		Sorafenib	Placebo		Sorafenib	Placebo		
	<i>N</i>	177	56	129	50		85	40		39	20		
		<u>Median benefit</u>		<u>Median benefit</u>		<i>P</i> -value*	<u>Median benefit</u>		<i>P</i> -value*	<u>Median benefit</u>		<i>P</i> -value*	<i>P</i> -value†
	5 years	12m	6m	12m	1m	0.04	6m	4.5m	0.24	7.5m	1m	0.30	0.04
Baseline	15 years	12m	9m	12m	1m	0.03	6m	3m	0.11	7.5m	4.5m	0.18	0.02
prognoses	65%	5%	4%	5%	1.5%	0.15	3%	2%	0.02	4%	1%	0.34	0.02
	85%	3%	2%	2%	1%	0.16	1.5%	1%	0.47	1%	1%	0.42	0.12

m, months; * *P*-values from a mixed model applied to the normal score transformed benefit values with the following covariates fitted: treatment group, baseline benefit value, time point, and a time point by treatment group interaction. † *P*-value from mixed model as above but without the time point by treatment group interaction (i.e. treatment effect assumed to be constant post-baseline).